All posts by imreal

Vero Naturals Offers Free Green CBD Powder to Any Organization or Brand Interested in Conducting Case Studies on the Effectiveness of CBD and Cannabidiolic Acid


Right now, there is minimal research on CBDA and we have the power to change this. When analyzed in a leading lab, Vero Naturals’ gCBD powder showed CBDA as the most potent cannabinoid.

Vero Naturals, an innovative business to business ingredient provider of the world’s first Nano green cannabinoids also known as gCBD, has announced it will provide any interested brands or organizations with free gCBD to conduct case studies. The initiative has launched in order to help further demonstrate the effectiveness of CBD and the hemp plant’s various helpful compounds, such as cannabidiolic acid (CBDA), which is profoundly present in gCBD.

CBDA is one of the most powerful and effective cannabinoids that is naturally produced in the cannabis plant and has been found to be 1,000 times more potent than CBD in reducing acute nausea. CBD comes from CBDA as it is a precursor for the compound and it is only turned into CBD if the plant is exposed to a chemical process known as decarboxylation. Unfortunately, extraction processes including CO2 that most companies currently utilize decarboxylate the CBDA into CBD. These extraction processes lead to capturing only a portion of the plant’s more than 500 compounds thereby rendering them unable to provide the powerful Natural Entourage Effect that is delivered by the original plant. This means, when case studies are conducted using a non-gCBD product, they are not utilizing the plant to its full potential.

Vero Naturals’ patented Particle Reduction Process does not decarboxylate the cannabinoids nor use chemicals or CO2, to turn the hemp plant into an ultra-fine green powder that houses a multitude of beneficial compounds, including CBDA plus other cannabinoids and terpenes that are typically lost during most extraction processes. The particle reduction process ensures the powder has a maximum bioavailability for increased metabolic absorption and effectiveness. Vero Naturals gCBD is the whole plant in powder form containing Nano sized particles, which is something no other CBD company can offer. It provides the end consumer with more benefits than traditional CBD oil, balm or isolate. Furthermore, the particle reduction process results in the most effective, 100 percent Natural Entourage Effect possible.

“Vero was born to move the cannabis industry forward and through this initiative, I believe we can do just that,” said Vero Naturals President and Co-founder, Rory Millikin. “Right now, there is minimal research on CBDA and we have the power to change this. When analyzed in a leading lab, Vero Naturals’ gCBD powder showed CBDA as the most potent cannabinoid. Up until Vero’s gCBD was recently commercially released, it was very difficult to obtain CBDA in any kind of quantity thus there is an unfortunately low amount of research and trials on this incredible acidic that was discovered by the Godfather of Cannabis, professor Raphael Mechoulam of Hebrew University, Jerusalem. However, each study that has been conducted shows incredibly promising results. We feel confident that by providing those interested in conducting case studies on CBD and/or CBDA with free gCBD, we can make a difference in millions of lives.”

Studies have found that CBDA doesn’t simply interact with the endocannabinoid system, it works by inhibiting the cyclooxygenase-2 (COX-2) enzyme, which is associated with inflammation. Additional studies found that CBDA might influence serotonin-related 5-hydroxytryptamine (5-HT) receptors, which is an important discovery for cancer patients, individuals with mental health disorders, those prone to epileptic seizures, and more.

Millikin continued, “This is the ideal time for brands to do right by their customers by dedicating time to researching the best quality ingredients that are not only effective but are clean. Additionally, research organizations can utilize our free gCBD to elevate their studies and have the potential to change the world through their findings. This is a unique time we are living in, but one thing that stays constant is the need for impactful discoveries that might lead to amazing products.”

Leading CBD expert, Harvard University graduate, author and former United States Army Medic, Dr. Gregory Smith said, “I have utilized gCBD in various case studies and can confidently say that there is nothing else on the market that compares in quality, wholeness, effectiveness and bioavailability. The current studies on CBDA are incredibly promising and if the discoveries hold true, this compound that is found extensively in Vero’s gCBD truly can make an impact on many lives.”

Vero Naturals Green CBD is currently used in popular consumer brands such as Kopari Beauty which is available at Ulta nationwide and has already seen large success and outstanding feedback from customers that entrust the products and brands to offer them unique products made with real ingredients like Vero Naturals.

Brands interested in partnering with Vero Naturals to create their clinical trial are invited to get in touch with Rory Millikin at rory@veronaturals.com. Limited quantities of free gCBD are available and the amount will be determined upon consultation. For more information on Vero Naturals please visit http://www.veronaturals.com.

###

About Vero Naturals

Vero Naturals is an ingredient supplier to brands that has created the first B2B green Nano CBD Powder and Liposomes in the market. Vero Naturals has both patents issued and over 20 pending in a multitude of sectors within the cannabis industry. For more information, please visit http://www.veronaturals.com

Share article on social media or email:

Tammie Arnold Joins Sonen Capital’s Board of Directors


Social & Environmental Impact Investment Management

Tammie is an accomplished leader whose passion for advancing the field of sustainable and impact investing is highly aligned with Sonen’s mission.

Sonen Capital LLC, an investment management firm focused exclusively on impact and sustainable investing and advice, is pleased to announce that Tammie Arnold has joined its Board of Directors. Ms. Arnold brings over 25 years of experience in the investment management industry, much of which is focused in the areas of sustainability and impact.

Ms. Arnold has had a distinguished career in the sustainable investment management field, having most recently been a Partner at Generation Investment Management where she was a member of their Management Committee and, prior to that, serving as a Managing Director at the Pacific Investment Management Company (PIMCO), where she was a member of their Executive Committee. At PIMCO, Ms. Arnold led the integration of sustainability into their investment process and into their secular economics forum. Ms. Arnold also serves on the Board of Directors of the World Resources Institute.

“Tammie is an accomplished leader whose passion for advancing the field of sustainable and impact investing is highly aligned with Sonen’s mission,” said Stuart Davidson, Sonen’s Co-Founder and Chairman of the Board. “We look forward to Tammie’s unique and insightful perspective as Sonen continues to grow and innovate on behalf of its clients and the world of impact. We are very excited to have her join our team.”

“I am thrilled to join Sonen’s Board,” said Ms. Arnold. “Sonen has been at the forefront of impact investing for many years, and I have the highest regard for the team they built and the work they have done in this space over the years. I look forward to helping Sonen further their efforts in impact, which couldn’t be more important given the many challenges we face today as a society.”

About Sonen Capital LLC

Sonen Capital is a specialized impact investment management firm headquartered in San Francisco, CA. Sonen invests on behalf of institutions, family offices, high net worth individuals, foundations and endowments seeking both exceptional financial returns as well as social and environmental sustainability. http://www.sonencapital.com

Share article on social media or email:

Easyriders announces an Exclusive Licensing Agreement with Big Top Farms and Hemp2Lab to collectively innovate and create high-quality CBD


Easyriders Hemp Pre Rolls

Pepper Foster from Easyriders: “It was important for us to find a team of seasoned business executives with strong operational expertise, vast farming experience, proven scientific knowledge, and innovative product formulation capabilities who are passionate about making a difference.”

Easyriders announces an Exclusive Licensing Agreement with Big Top Farms from Sisters, OR. and Hemp2Lab from Rossville, TN. to collectively innovate and create high-quality CBD hemp oil products for the Easyriders brand

Pepper Foster, President and Publisher of Easyriders, the rock-n-ride brand legend named with a nod to the eponymous cult film classic that recently celebrated its 50th Anniversary, has partnered with Sykes Mitchell, CEO of Big Top Farms, a world-class farming operation in Sisters, Oregon, and Bill Margaritis, President & CEO of Hemp2Lab a new leading-edge extraction lab in Rossville, Tennessee, to produce specially curated high-quality CBD hemp oil products.

Easyriders completed an exclusive six-year multi-million dollar licensing deal that will take them through the end of 2025. Easyriders will enter the growing CBD marketplace with products such as creams, tinctures, CBD/CBG consumables, oils, raw flower, and pre-rolled 7 packs.

Pepper Foster from Easyriders states: “It was important for us to find a team of seasoned business executives with strong operational expertise, vast farming experience, proven scientific knowledge, and innovative product formulation capabilities who are passionate about making a difference in the hemp space. We are in active discussions with several high-profile brands who are very motivated in carrying our hemp products, both online and in storefronts.”

Big Top Farms and Hemp2Lab will provide custodial care of the exceptionally curated products they produce through best-of-class farming and laboratory science. This integrated business partnership will cover the entire spectrum of farming, laboratory processing, fulfillment functions, and customer experience services to bring innovative Easyriders CBD products to market.

Sykes Mitchell, CEO of Big Top Farms states: “Farming hemp is both a science and an art. We’ve perfected our formula over the years with a passion of being good stewards of the land. We’re excited about the possibilities of bringing premium artisan crafted hemp products to market with the Easyriders brand.”

Bill Margaritis, President & CEO Hemp2Lab states: ”Consumers expect quality, consistency, and safety when they purchase hemp-based products, and we aim to fill that void with best of class products. The current market is littered with low quality, bogus products, and we believe there’s a great opportunity for us to earn consumers’ trust and confidence with product integrity and quality.”

Big Top Farms is central Oregon’s premier, family-owned large-scale farming operation, specializing in sustainably grown, terpene rich, high-content CBD and CBG hemp, using best-of-class genetics and organic inputs; and Hemp2Lab is a newly built state-of-the-art laboratory in Rossville, Tennessee, with a proprietary method of extracting hemp oils using the finest equipment and technology under the watchful eye of a 34-year chemical industry veteran, Dr. Randall W. Powell, PhD, former VP of manufacturing, and research and development at Eastman Chemical Company.

Under the new ownership of brand-maker Pepper Foster, Easyriders will expand the vision of what it means to be a motorcycle enthusiast in the 21st century. As part of the 50th anniversary of the Easyriders brand, the company’s strong heritage and global community is evolving into a contemporary motorbike lifestyle brand through successfully growing and expanding the demographics to include 18- to 35-year-olds. Easyriders will create all of the package design and branding, and will invest in marketing and promotion of its name brand hemp product line.

The company is pursuing exclusive partnerships through targeted brand collaborations in all major categories including (but not limited to) apparel, footwear, jewelry, accessories, camping, outdoors as well as digital media and entertainment. With millions of loyal biker enthusiasts who are very familiar with the Easyriders brand, the company reports that more than 50 percent of the people joining its social media platforms are millennials. This discovery shows that the Easyriders brand has cross-demographic appeal that can be leveraged into the future growth of the company.

Easyriders magazine and its new website launched January 2020.

About Easyriders:

In 1970, Easyriders was established as a platform for motorcycle enthusiasts to immerse in the rugged, on-the-road lifestyle championed by the counterculture movement and legendary riders. More than a magazine, Easyriders is now a lifestyle brand. In celebration of the 50th anniversary, Easyriders is expanding the brand to encompass exclusive, major-label product collaborations, insider events, and a quarterly coffee table–style book jam-packed with gorgeous photography and feature stories. With a nod to Easyriders’ roots in independence, passion, and freedom, and with newfound emphasis on international travel, design, and entertainment, Easyriders has flown full throttle into a new era.

About Big Top Farms: is a premier, family owned, large-scale farming operation in Oregon, specializing in sustainably grown, terpene rich, high-content CBD and CBG hemp, using best-of-class genetics. Big Top Farms is dedicated to using organic inputs and to remaining pesticide free, focusing on purity, quality, and consistency. Situated in a unique microclimate in the shadow of the Cascade Mountain range, the soil and air are ideal for hemp. The family has been farming hemp, testing seed genetics, and formulating their own small-batch hemp oil recipes for over four years and brings a heritage of six generations of farming experience to the partnership.

For more information visit:

https://www.easyriders.com

https://www.instagram.com/easyriders/

Press Information:

Jennifer Gross | Julia Axelrod

Evolutionary Media Group

Jennifer@emgpr.com | Julia@emgpr.com

323-658-8700



PDA Forms Coronavirus Pandemic Response Task Force, New Advanced Therapy Advisory Board


PDA, Inc.

The Parenteral Drug Association, Inc. (PDA) today announced two new volunteer opportunities and changes to its Board of Directors/Executive Committee following its spring Board of Directors meeting.

In response to the current global pandemic and its impact on manufacturing and supply chains, PDA’s Board chose to form a Coronavirus Pandemic Response Task Force. Consisting of volunteers from leading bio/pharmaceutical manufacturers, the Task Force will develop strategies to ensure the continued manufacturing and supply of product during an active outbreak with a specific focus on regulatory requirements as well as good manufacturing practices (GMPs) processes and controls. The end goal is to elucidate steps manufacturers can take to ensure the ability to meet current as well as increased supply demands for pharmaceutical products during these events. The Coronavirus Pandemic Response Task will be led by Anil Sawant, Merck & Co., who also sits on the PDA Board of Directors.

Recognizing the growing importance and impact of cell and gene therapy products, the Board resolved to create an Advanced Therapy Medicinal Products Advisory Board. This new advisory board will oversee PDA projects and Interest groups in these areas as well as provide guidance to PDA in the development of events, trainings, and technical publications to assist companies developing gene therapy medicinal products, somatic cell therapy products, and tissue engineered products. Two PDA Directors, Michael Blackton, VP Global Quality, Adaptimmune, LLC, and Stephan Krause, PhD, Head of Product Quality, AstraZeneca Biologics, have been appointed to form and lead the new advisory board.

PDA also named new members to its Board of Directors, as Glenn Wright left the all-volunteer body to join PDA staff as the Vice President of Scientific and Regulatory affairs in March. Melissa Seymour, Biogen, Inc., assumed the role of Treasurer; Emma Ramnarine, Roche Pharma, assumed the role of Secretary, and Stephan Roenninger, Amgen joined as a Director.

For more information about PDA, its volunteer boards and committees, and leadership, got to PDA’s website, http://www.pda.org.

About PDA – Connecting People, Science and Regulation®

The Parenteral Drug Association (PDA) is the leading global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community. Founded in 1946 as a nonprofit organization, PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of over 10,500 members worldwide. PDA is an ANSI accredited Standards Developing Organization. Go to http://www.pda.org/footer/about-pda to learn more.

Share article on social media or email:

COVID-19 Crisis Focuses Attention on Oft-Overlooked Vaccine Industry


Kalorama Information logo

As the COVID-19 outbreak advances worldwide, companies are scrambling to provide a potential vaccine. Companies from all over the world have stepped up to the challenge. There are 78 confirmed COVID-19 vaccine candidates, 5 of which have already entered clinical trials. This is documented in Kalorama Information’s recent report: Vaccine Development and Production Trends – COVID-19 and Other Vaccines Pipeline. The report presents a list of companies that have stepped up to develop a vaccine for COVID-19. The list is certain to multiply in the coming weeks as efforts are stepped up to combat COVID-19.

The report notes that although COVID is getting most of the attention, there are vaccine efforts underway for a host of diseases – including HIV, breast cancer therapeutic vaccines, malaria and Zika. Kalorama documents vaccine candidates with significant progress and those on the World Health Organization tracker.

Vaccines are often not paid much attention to compared to their pharmaceutical therapeutic brethren certainly. A few companies make them, with the help of large volume production suppliers — including egg farms and cell media vendors. Vaccines are probably the most disparate of all biologicals, and are large-volume products. Vaccine types range from relatively simple peptides to entire cells, and a limited number of manufacturing methods are available for each vaccine. Vaccines are administered in fewer and smaller doses to a much larger patient population than other biologicals. Per dosage prices are a miniscule fraction of non-vaccine biologicals and there is little manufacturer financial incentive to modify production technologies.

Prior to regulatory approval, a vaccine candidate usually undergoes three phases of development in humans, which, for the most part, progress sequentially: Phase I, Phase II, and Phase III. After successful completion of Phase III trials and following licensure of the product, Phase IV studies, doses are received by healthy individuals, thus the safety margin should be very high.

All this being said, there is remarkable progress with COVID-19 vaccines. Four companies already have vaccines in Phase 1 development, which is a remarkable accomplishment given the complexity and time needed to develop a vaccine:


  • CanSino Biologics is developing a vaccine for the prevention of COVID-19, Ad5-nCoV, a recombinant vaccine incorporating the adenovirus type 5 vector. On March 8, 2020, CanSino received approval from the Chinese authorities to being human trials. This is the first coronavirus vaccine to advance to Phase 2 trials.
  • Moderna offers its MRNA-1273, a novel lipid nanoparticle-encapsulated mRNA vaccine encoding for a perfusion stabilized form of the Spike (S) protein. On March 16, 2020, the company began its Phase 1 open-label, dose-ranging trial, occurring at Kaiser Permanente Washington Health Research Institute in Seattle.
  • Inovio Pharmaceuticals announced that CEPI provided a grant to develop a vaccine against COVID-19 called INO-4800. The company is collaborating with Beijing Advacine Biotechnology to advance the product. Preclinical testing has begun with human clinical trials to commence in April 2020 in US, China and South Korea. It is anticipated that with positive results that 1 million doses of INO-4800 DNA vaccine can be produced by the end of 2020. On April 6, 2020, the company received approval to begin Phase 1 trials. The Bill and Melinda Gates Foundation, along with other nonprofits, are putting money into Inovio’s COVID-19 vaccine project.
  • Shenzhen Geno-Immune Medical Institute offers LV-SMENP-DC vaccine. The LV-SMENP-DC vaccine is made by modifying DC with lentivirus vectors expressing Covid-19 minigene SMENP and immune modulatory genes. CTLs will be activated by LV-DC presenting Covid-19 specific antigens. The project is in Phase 1.
  • The company has a second product, Covid-19/aAPC vaccine. The Covid-19/aAPC vaccine is prepared by applying lentivirus modification including immune modulatory genes and the viral minigenes, to the artificial antigen presenting cells (aAPCs). It is also in Phase 1.

Kalorama’s report details all of these projects. It can be found at: https://kaloramainformation.com/product/vaccine-development-and-production-trends-covid-19-and-other-vaccines-pipeline/

About Kalorama Information

For more than 30 years, Kalorama Information has been a leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), imaging, biotechnology, healthcare, medical devices, and pharmaceuticals.

Share article on social media or email:

As COVID-19 Supply Shortages Affect First Responders and Patients, New Jersey Compounders Step In by Making Hand Sanitizers and Drug Alternatives


Lieutenant Butler (left), Sargent Burke (center), Lieutenant Rotondi (right) of the Hoboken Police Force will disperse the donated hand sanitizers to their on-duty officers during COVID-19 pandemic.

“We have been asked to compound many medications, such as azithromycin (Z-Pak), that is now in shortage because of the virus,” says John Herr, RPh., pharmacist and owner of Town and Country Compounding Pharmacy.

COVID-19 has uncontrollably spread globally, with total cases rising over 950,000 in the United States alone, according to the Centers for Disease Control and Prevention (CDC). Shortages in essential supplies have affected individuals in many high-risk populations.

Fearing infection, the world responded to the novel coronavirus with panic buying of toilet paper and sanitation products, such as disinfectants and hand sanitizers. Commercially produced hand sanitizer companies are unable to meet unexpectedly significant increases in demands, leaving many out of luck.

First responders such as health workers, law enforcement and grocery clerks are at the frontlines, risking their health with every uncertain encounter. As social distancing is not an option for these essential workers, regular cleaning of hands, while avoiding touching of the eyes and face, can make all the difference.

Town and Country Compounding Pharmacy in Ridgewood, New Jersey, donates hand sanitizers to local first responders. The hand sanitizers comply with the guidelines set by the World Health Organization (WHO), effective against the novel coronavirus.

Christina DiMartino, CPhT. of Town and Country, who has been processing and receiving prescriptions from her home during the pandemic, has a deep connection with the Hoboken Police Force. Her son Joey is especially enthusiastic about helping the force that his father Joseph DiMartino, and uncles, David DiMartino and Keith Rotondi, are a part of. Upon hearing about the donations for first responders, Joey thought of his heroes and keeping them safe while on-duty.

Town and Country donated hand sanitizers to the Hoboken Police Department to help authorities keep themselves safe, as they protect and serve residents in the time of the COVID-19 pandemic.

Hoboken Police Force Chief, K. Ferrante, and the rest of the department have expressed appreciation for the donation by Town and Country Compounding Pharmacy.

Shortages in medication supplies have also surfaced, as the crisis rages on and researchers look to existing drugs to treat COVID-19.

Pharmacists are working tirelessly to provide for the health needs of patients, in the face of shortages during this crisis. “We have been asked to compound many medications, such as azithromycin (Z-Pak), that is now in shortage because of the virus,” says John Herr, RPh., pharmacist and owner of Town and Country Compounding Pharmacy. Many people utilizing these medications are being left empty handed, or must wait for supplies to be replenished.

Furthermore, the use of Hydroxychloroquine (Plaquenil) for COVID-19 positive patients has recently come to light, and is creating shortages for those that use it to treat autoimmune conditions such as lupus or rheumatoid arthritis.

To keep up with increased demand as the number of COVID-19 positive cases continue to increase, compounders are working with providers to offer Low Dose Naltrexone (LDN) as an alternative for treating autoimmune conditions as shortages continue. John Herr, RPh., is one of the nation’s top LDN experts, educating patients and providers about current advancements and developments.

As our nation, and the world, seek to contain the spread of COVID-19, pharmacists continue doing their part to serve the public through compounding.

About Town & Country Compounding

As the pandemic continues, Town & Country Compounding makes it a point to help prevent the spread of COVID-19, all while serving the needs of the community in its entirety. As part of its commitment, Town and Country Compounding Pharmacy also offers hand sanitizer, cloth and surgical masks available for purchase to customers picking up prescriptions and supplements, with shipping to anyone in need also available.

Visit TCCompound.com for more information, shipping to 12 states and Washington D.C. If you know first responders that are in need of hand sanitizer, or if you are in need of medications, supplements, or prescriber referrals please call (201) 447-2020.

Share article on social media or email:

LAVA Launches LTS Connectivity Adapters for Lenovo Tablet-based Systems


LAVA LTS vc2UE

The way how users interact with tablets is changing with emphasis on using consumer tablets for commercial tablet kiosk and cradle systems. Enhanced tablet capabilities are more critical than ever to give developers robust tools without limitations.

– SimulCharge, the Lava technology that allows a tablet to be charged while connecting to external peripherals is now available for Lenovo tablets.


  • Configurations include Ethernet, USB Hub, and combinations. Powering options include direct 5V wall charger supply, PoE or extended Power Controller version (VC) for enhanced powering capabilities.
  • Each adapter includes Lava’s proprietary Charge and Battery Modulation (CABM) technology that monitors the charging characteristics of the tablet and modulates the charging cycle to ensure that the battery is never over charged. This technology increases battery life span by a minimum of 3 fold and is indispensable for 24/7 operation.

LAVA Computer MFG Inc., a Canadian based manufacturer of interfaces for mobile devices and computers, has released its new line of Lenovo Tablet SimulCharge (LTS) connectivity adapters developed for tablet-based systems. Thoughtfully designed for the evolving demand of new tablet configurations, LAVA’s latest LTS products provide powerful new ways to connect, create, and protect tablet-based hardware applications operating 24/7.

SimulCharge and CABM Technology: Fuelling Tablet Connectivity and Charging

With LAVA’s plug-and-play SimulCharge (Host/OTG Charge) mode built into LTS adapters, the tablet is not limited to a single USB port but expanded into a gateway for connecting multiple USB peripherals, wired Ethernet and simultaneous charging via Power over Ethernet (PoE), AC/DC adapter or a tablet Micro USB charger.

LAVA’s exclusive Charge and Battery Management (CABM) technology keeps the tablet battery protected from overcharging when powered 24/7, and prolongs tablet’s battery lifespan up to 3 years. This technology allows Lenovo consumer tablets to be used as a commercially viable tablet-based solution.

LAVA’S LTS Adapters: Turning a Consumer Tablet into a Commercial Tablet System

According to Roman Wynnyckyj, LAVA’s founder and CEO: “The way how users interact with tablets is changing with emphasis on using consumer tablets for commercial tablet kiosk and cradle systems. Enhanced tablet capabilities are more critical than ever to give developers robust tools without limitations.”

As part of this changing landscape, LAVA teamed up with Lenovo to unveil LTS tablet connectivity adapters to fulfill a commitment of expanding SimulCharge and Battery Modulation enabled adapters beyond Samsung compatibility. With over a million LAVA products built into tablet-based systems used in retail, logistics, healthcare, education and government, LAVA products are trusted by resellers, distributors, OEMs and system builders in over 47 countries worldwide.

The LTS SimulCharge and CABM line of adapters is available worldwide at http://www.lavasimulcharge.com.

https://twitter.com/LAVALink

https://www.facebook.com/LavaComputer/

https://www.linkedin.com/company/9176364/

Share article on social media or email:



Dogtown Media and Late Sunday Afternoon Partner with Schusterman Family Foundation to Provide Protective Masks for Frontline COVID-19 Healthcare Workers


As the novel coronavirus (COVID-19) continues to wreak havoc around the world, medical providers are struggling with short supplies of personal protective equipment (PPE). To address this growing problem, mobile app developer Dogtown Media has teamed up with apparel company Late Sunday Afternoon and the Schusterman Family Foundation. Together, the three organizations are donating reusable, washable protective masks to healthcare facilities across the United States.

When the state of California was hit with its first few cases of COVID-19, Late Sunday Afternoon Founder and CEO Matthew Schildkret immediately shuttered his clothing shop’s doors. His business was considered non-essential, and he did not want to put the health of his employees at risk. But as the coronavirus crisis unfolded in the U.S., it became clear that medical facilities needed all the help they could get. The current PPE shortage leaves numerous healthcare providers and patients susceptible to contracting and spreading COVID-19. Desperate times call for innovative measures.

Schildkret discussed the dilemma with Dogtown Media Co-Founder and CEO Marc Fischer. Together, the two created a strategy to help out: Create a 1-for-1 protective mask donation campaign. Within the first hour of launching, the campaign received hundreds of orders. To deal with the demand, Schildkret immediately sprung into action. He retooled his clothing company’s equipment and brought in a few of his team members to ramp up production. Within a week, the campaign quickly scaled to thousands of placed orders per day.

Fischer sought ways to amplify his and Schildkret’s efforts. Fortunately, the Charles and Lynn Schusterman Family Foundation was more than happy to help. The organization has offered to provide a generous micro-grant of $2500. With these funds, Schildkret and Fischer plan to send protective masks to multiple organizations, including Minneapolis-based nonprofit Allina Health; New York-Presbyterian/Columbia University Medical Center; Columbus Colony Elderly Care in Ohio; and other care facilities across the nation.

Located in Los Angeles, Late Sunday Afternoon is a clothing company that hand-crafts functional, comfortable, and stylish apparel. It sources materials locally and employs a conscientious production process to promote zero waste and sustainability.

The Charles and Lynn Schusterman Family Foundation is a global philanthropic organization that strives to improve lives by empowering communities and advancing equity. It invests in efforts that enhance public education and address the needs of marginalized individuals.

Headquartered in Venice Beach, California, Dogtown Media is a mobile technology studio that leverages disruptive design strategies and dynamic development to deliver industry-leading apps. To date, the company has created over 200 mobile apps in industries including Healthcare app development, IoT, and Artificial Intelligence.

For more information about Late Sunday Afternoon’s 1-for-1 campaign, click here.

Share article on social media or email:

Soter Technologies Introduces Rapid Walk-Through Health Detection Scanner to Reduce the Spread of Illness and Assist with the Opening of the Economy


SymptomSense™ uses an array of sensors to provide a rapid, non-invasive, hands-free approach for gaining important real-time vital signs, including detecting: blood oxygen levels and, external body temperature within 0.2 degrees of accuracy

Soter Technologies’ team of engineers and medical advisors have been working around the clock since December 2019 to create, design and build technology to help reduce the spread of the COVID-19 pandemic, other illnesses and to aid with the re-opening of the economy. The company is best known for the international headlines it has generated as the inventors of the world’s first K-12 school vape detection sensor and alert system, FlySense™.

Soter Technologies announced today that the SymptomSense™ Medical Evaluation Gateway, a non-invasive walk-through electronic full-body symptom scanner for providing detection of symptoms of known illness in less than 10 seconds is now moving into the production phase.

SymptomSense™ is a revolutionary electronic walk-through full-body health scanner that looks similar to metal detectors used at security checkpoints of airports, sporting events and government buildings. Similar to the rapid evaluation that an individual would receive at a hospital emergency room SymptomSense™ gathers critical vitals including blood oxygen level, which is more important than body temperature, when assessing if an individual is ill.

SymptomSense™ uses an array of sensors to provide a rapid, non-invasive, hands-free approach for gaining important real-time vital signs, including detecting: blood oxygen levels, external body temperature within 0.2 degrees of accuracy (Celsius), elevated heart rate, respiration rate, shortness of breath, lung congestion, height, weight and, in the future, non-contact blood pressure. Within seconds the SymptomSense™ device provides health status with clear messaging and indicators for screening staff, and, in the future, data mapping of alerts to an electronic system-of-records that can be shared with authorities as may be required per local laws and ordinances.

“To get the economy going, open schools and allow for people to safely work and gather we need to use sensor technology and continue to follow recommended safety protocols. At Soter we identified months ago, with our medical advisors, that it is critical to check body temperature. However, to get a better idea if an individual is ill, we also determined that we would need to know blood oxygen level, check heart and respiration rates and identify if there is lung congestion. Our technology combines all this data to make a more effective identification of potential illness,” Derek Peterson, CEO of Soter Technologies.

The development and beta testing of prototypes started in late 2019 in response to the COVID-19 outbreak in China. Fortune 100 companies, major league professional sports teams, entertainment parks, Broadway theater management companies, real estate development and management companies, U.S. federal government departments and governments around the globe have all expressed interest and are reviewing SymptomSense™ for potential use.

SymptomSense™ allows on-site security personnel to rapidly screen and use the Soter’s AI (Artificial Intelligence) technology to identify individuals with known symptoms prior to entry into hospitals, schools, airports, train stations, government buildings, military bases, stadiums, malls, and other such facilities that must remain open. Soter has accepted orders from clients in the United States, Europe and countries around the world with delivery of the first units set for June 2020.

The company formed an Advisory Board of doctors, scientists and engineers that continues to work with the medical and research community to enhance the systems’ technology and capabilities. For example, SymptomSense™ now includes a module for weapons detection to provide property managers with an all-in-one access reassurance solution.

“We have learned from the COVID-19 pandemic that we must be much more vigilant and leverage technology to keep the public safe and stop the rapid spread of disease. SymptomSense™ creates an early warning system that will aid in reducing the community spread of viruses including the flu as well as other illnesses,” said PK Carlton, Jr, Lt Gen (Ret) USAF MD, FACS, and former Surgeon General of the U.S. Airforce.

“The rapid spread of the COVID-19 virus and the serious threat it poses to lives requires us to act now. Based on my discussions with the engineers at Soter Technologies and other medical advisors involved with development, I believe that the SymptomSense™ device is an effective screening and critical information sharing tool which could reduce the spread of COVID-19 disease and future biological threats,” said Cardiologist, Mordecai N. Klein, MD, FACC.

SymptomSense™ can scan approximately 1,500 people per hour and is capable of processing over 10,000 people over an 8-hour period, with zero downtime. For airline and other transportation systems, an optional built-in facial recognition technology is available for data-mapping to government registry. In doing so, SymptomSense™ platform enables building / site security personnel to track the movement of potential carriers of a virus, while protecting their privacy. This data capture and mapping capability is critical for understanding the current and predictive patterns, and trending for the spread of disease, and then help trace back to most-current disease geo-location clustering and origin. As needed, the platform can be linked to mobile phone “contact tracing” data, local weather data, and demographic data as may be required by government agencies.

“The world is in the midst of an existential international health and economic crisis. However, it is now clear that we need to use technology to create a healthier and safer world. Since December 2019 we brought a team together that is using best-in-class technology, which includes internal and external environmental sensors, artificial intelligence software, the Internet-of-Things data sharing, agnostic wireless connectivity to rapidly collect, process and share data that will help reduce the short and long term impact of the COVID-19 pandemic. This technology has been incorporated into SymptomSense™ to identify individuals who present symptoms. In doing so, these individuals will receive care more rapidly. This process will also limit the exposure of healthy and at-risk populations to illness,” added Peterson.

The company is accepting United States and international orders for SymptomSense™ Scanners. This health and safety technology platform can be deployed rapidly and is easy to use.

For information about SymptomSense™ pricing, specifications and ordering go to https://www.symptomsense.com/. For more information about Soter Technologies visit http://www.sotertechnologies.com.

-END-

About Soter Technologies

Ronkonkoma, New York-based Soter Technologies is committed to protecting the health and wellbeing of students and the public with advanced technology and creative solutions. Using advanced sensor, IoT and software technology, Soter Technologies develops and delivers innovative solutions for environmental intelligence – to make the world a safer and healthier place, from schools to enterprises to public spaces. Taking a holistic approach to safety and security, Soter provides technology tools to detect and deter without invading privacy. The company was founded as Digital Fly™ in 2015 – focused on social media awareness. The company is the first in the world to introduce a vape and bullying detection and alert system for schools – FlySense™ Vaping & Elevated Sound Detector. The company now has technology to detect illness and protect critical facilities from those who may have or be carriers of viruses or other communicable illnesses. The company’s technology has been embraced by schools across the United States and around the world. The Soter name is inspired by Greek mythology wherein Soter is the personification of safety, deliverance, and preservation from harm. For more information about the company, its services and products visit: http://www.sotertechnologies.com.